APA (7th ed.) Citation

P, D., JD, G., EN, E., M, K., TB, D., J, F., . . . N, P. (2022). Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: Benefits of physician selective testing. Breast cancer research and treatment, 191(3), 501. https://doi.org/10.1007/s10549-021-06456-5

Chicago Style (17th ed.) Citation

P, Dinh, et al. "Impact of the EndoPredict Genomic Assay on Treatment Decisions for Oestrogen Receptor-positive Early Breast Cancer Patients: Benefits of Physician Selective Testing." Breast Cancer Research and Treatment 191, no. 3 (2022): 501. https://doi.org/10.1007/s10549-021-06456-5.

MLA (9th ed.) Citation

P, Dinh, et al. "Impact of the EndoPredict Genomic Assay on Treatment Decisions for Oestrogen Receptor-positive Early Breast Cancer Patients: Benefits of Physician Selective Testing." Breast Cancer Research and Treatment, vol. 191, no. 3, 2022, p. 501, https://doi.org/10.1007/s10549-021-06456-5.